JP MORGAN/PUT/VERTEX PHARMACEUTICALS/400/0.1/17.01.25 | Delayed Börse Stuttgart 01:52:44 05/07/2024 pm IST | ||
| 1.05 EUR | -0.94% |
|
| Current month | -0.93% | ||
| 1 month | -22.06% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 05/24/05 | 1.05 | -0.94% |
| 04/24/04 | 1.06 | +7.07% |
| 03/24/03 | 0.99 | -4.81% |
| 02/24/02 | 1.04 | -7.96% |
| 01/24/01 | 1.13 | +5.61% |
Delayed Quote Börse Stuttgart
Last update July 05, 2024 at 01:52 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | J.P. Morgan |
| WKN | JB95Z6 |
| ISIN | DE000JB95Z62 |
| Date issued | 21/12/2023 |
| Strike | 400 $ |
| Maturity | 17/01/2025 (197 Days) |
| Parity | 10 : 1 |
| Emission price | 3.3 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.11 € |
|---|---|
| Lowest since issue | 0.99 € |
| Spread | 0.3 € |
| Spread % | 22.22% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
470.3
USD
Average target price
468.3
USD
Spread / Average Target
-0.43%
- Stock Market
- Warrants
- Warrant
